medac GmbH clinical trials
The registry lists 27 studies whose lead sponsor is medac GmbH or the company grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 12, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 27studies on the registry
- 2open to participants now
- 2phase 3 studies under way
- 2reach primary completion within a year
Get an email when these change. Save the medac GmbH studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs medac GmbH’s studies test, most open studies first — 6 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- Methotrexate1 in phase 31 open · 3
- treosulfan1 in phase 30 open · 7
- Aminolevulinic Acid1 in phase 30 open · 3
- Urokinase-Type Plasminogen Activator1 in phase 30 open · 2
- 0 open · 1
- 0 open · 1
Coming up
2 of medac GmbH’s studies under way reach primary completion within a year, all of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- 1NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- 1AAug
- SSep
- OOct
- NNov
All 2
- Nov 2026Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.Methotrexate · Phase 3 · NCT06239311
- Aug 2027Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available TherapyPhase 3 · NCT04629833
Add all 2 to your calendar (.ics) → With an account.
All 27 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 308
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 8 started before 2008. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to medac GmbH.
- medac GmbH22 studiesSame company
Something wrong?
- photonamic GmbH & Co. KG5 studies →Divested — left medac GmbH, 2016 · 2 more first submitted after it left, not counted · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 27 of 27.
- Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.RecruitingNCT06239311Phase 3
- Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available TherapyRecruitingNCT04629833Phase 3
- Dose-range Finding Treosulfan-based ConditioningCompletedNCT01063647Phase 1/2
- Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan PharmacokineticsCompletedNCT05534620Phase 1
- Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host DiseaseActive, not recruitingNCT06075706Phase 2
- PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic LeukaemiaTerminatedNCT03156790Phase 2
- Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant DiseasesCompletedNCT02349906Phase 2
- Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)CompletedNCT00822393Phase 3
- Treosulfan-based Conditioning in Paediatric Patients With Haematological MalignanciesCompletedNCT02333058Phase 2
- Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic ArthritisCompletedNCT02052167Early Phase 1
- Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.CompletedNCT02355899Phase 2
Sponsor listed in the registry: photonamic GmbH & Co. KG · First submitted before photonamic GmbH & Co. KG left medac GmbH
- Fluorescence-guided Resection in Breast CancerTerminatedNCT01110954Phase 2
Sponsor listed in the registry: photonamic GmbH & Co. KG · First submitted before photonamic GmbH & Co. KG left medac GmbH
- Photodynamic Therapy of Actinic Keratoses With Alacare®CompletedNCT01571336
Sponsor listed in the registry: photonamic GmbH & Co. KG · First submitted before photonamic GmbH & Co. KG left medac GmbH
- Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant GliomasCompletedNCT02755142Phase 1/2
- Bioavailability in Patient With Psoriasis: Metoject Prefilled PenCompletedNCT02097173Phase 1
- Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)PatientCompletedNCT01871961Phase 1
- Urokinase Therapy in Patients With Diabetic Foot SyndromeTerminatedNCT00823225Phase 3
- Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)CompletedNCT01793259Phase 3
- Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult Patients With Newly Diagnosed Acute Lymphoblastic LeukaemiaTerminatedNCT01251809Phase 1/2
- Comparative Efficacy and Safety of Two Asparaginase Preparations in Children With Previously Untreated Acute Lymphoblastic LeukaemiaCompletedNCT00784017Phase 3
- Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic AcidCompletedNCT00241670Phase 3
- Efficacy and Safety of Recombinant Asparaginase in Infants With Previously Untreated Acute Lymphoid Leukemia (ALL)CompletedNCT00983138Phase 2
- Urokinase Therapy in Diabetic Foot SyndromeCompletedNCT00537498Phase 2
- Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)CompletedNCT01063660Phase 2
- Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)CompletedNCT01062490Phase 2
- PD P 506 A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AKCompletedNCT00308867Phase 3
Sponsor listed in the registry: photonamic GmbH & Co. KG · First submitted before photonamic GmbH & Co. KG left medac GmbH
- Photodynamic Therapy With PD P 506 A Compared With Placebo-PDT for the Treatment of AKCompletedNCT00308854Phase 3
Sponsor listed in the registry: photonamic GmbH & Co. KG · First submitted before photonamic GmbH & Co. KG left medac GmbH